Physician

Oncology

Sant Chawla practices Oncology. Sant Chawla has written publications. He has 48 publications published with PubMed. The lastest publication is: 'Tumor-associated fever in breast cancer.' Sant Chawla accepts Medicare.

Publications

---

• Ewing Sarcoma in a Patient With Cowden Syndrome.
• A phase 1B/2 study of aldoxorubicin in patients with soft tissue Sarcoma.
• Prognostic value of necrosis after neoadjuvant therapy for soft tissue Sarcoma.
• A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyoSarcoma, osteo...
• Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related Sarcomas.
• A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.
• Giant Cell Tumor of Bone in Childhood: Clinical Aspects and Novel Therapeutic Targets.
• Ridaforolimus in advanced or metastatic soft tissue and bone Sarcomas.
• Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim Analysis of an open-label, parallel-group, phase ...
• Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic Sarcomas in pa...
• Denosumab Induces Tumor ReDuction and Bone Formation in Patients with Giant-Cell Tumor of Bone.
• First-line treatment of metastatic or locally advanced unresectable soft tissue Sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase...
• Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas.
• R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase I...
• Treatment approaches to Sarcoma in the community setting.
• A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma.
• Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene deLivery.
• Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic Cancer.
• Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
• Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant Sarcoma and osteoSarcoma.
• Efficacy and safety of trabectedin in patients with advanced or metastatic lipoSarcoma or leiomyoSarcoma after failure of prior anthracyclines and ifosfamide: results ...
• Review: desmoplastic small round cell tumor: current treatment approach and role of targeted therapy.
• F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue Sarcomas.
• The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controll...
• Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
• Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
• Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable coloRectal cancer metastases.
• Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon Cancer refractory to 5-fluoroura...
• Cryosurgical ablation of soft tissue Sarcomas: a phase I trial of feasibility and safety.
• Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with Sarcoma: protection at the progenitor...
• Preoperative chemotherapy for osteoSarcoma with intravenous adriamycin and intra-arterial cis-platinum.
• Recovery of sperm proDuction after chemotherapy for osteosarcoma.
• OsteoSarcoma: angiographic assessment of response to preoperative chemotherapy.
• A comparative study of doxorubicin and epirubicin in patients with metastatic breast Cancer.
• Advanced basal cell carcinoma and successful treatment with chemotherapy.
• Phase I study of weekly-administered iproplatin [cis-dichloro-trans-dihydroxy-bis-isopropylamine platin (chip, JM9)].
• Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors.
• Effectiveness of chemotherapy in the management of metastatic telangiectatic osteoSarcoma.
• OsteoSarcoma chemotherapy effect: a prognostic factor.
• Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic Melanoma using two different schedules .
• ChondroSarcoma with additional mesenchymal component (dedifferentiated chondroSarcoma). I. A clinicopathologic study of 26 cases.
• Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and coloRectal carcinomas.
• Detorubicin--an active anthracycline in untreated metastatic Melanoma.
• Malignant fibrous histiocytoma of jaws. A clinicopathologic study of 11 cases.
• Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.
• Tumor-associated fever in breast Cancer.
• Eribulin versus dacarbazine in previously treated patients with advanced lipoSarcoma or leiomyoSarcoma: a randomised, open-label, multicentre, phase 3 trial.

Schools

---

• AllIndia Institute Of Medical Sciences AllIndia Institute Of Medical Sciences

• All India Institute Med Science

• All India Institute Med Scis

• Auckland Hospital

• Post Grad Institute Med Ed Rsch

• University Tex MD Anderson Hospital

Procedures Preformed

---

• Cancer Treatment

Conditions Treated

---

• Anal and Rectal Cancer
• Anemia
• Bile Duct Cancer
• Bladder Cancer
• View All

Doctors Specialties

---

• Internal Medicine
• Oncology

Accepted Insurances

---

Education

---

• University of Texas MD Anderson Cancer Center
• All India Institute of Medical Sciences

Hospital

---

• Cedars-Sinai Medical Center
• Keck Hospital of USC
• Ronald Reagan UCLA Medical Center

Drug Facts

---

NPI NUMBER		1508868837
NPPES Provider LastName		CHAWLA
NPPES Provider FirstName		SANT
NPPES Provider ZIPCode		904034803
NPPES Provider State		CA
Specialty Description		Hematology/Oncology
Total Claim Count		312.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1508868837
Last Name Of The Provider	CHAWLA
First Name Of The Provider	SANT
View All

Similar Doctors

---

	Dr. Brianna J. Cowan, MD This Doctor is OpenDoctor Recommended.
	Dr. Omid Hamid, MD This Doctor is OpenDoctor Recommended.
	Dr. Andrew E. Hendifar, MD This Doctor is OpenDoctor Recommended.
	Dr. Lawrence Piro, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Saeed W. Sadeghi, MD This Doctor is OpenDoctor Recommended.
	Dr. Kamalesh K. Sankhala, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog